Vasopressin Analog [V
5-FU
AVPR2
Antimetastatic
Co-adjuvant therapy
Colorectal cancer
[V4Q5]dDAVP
Journal
World journal of oncology
ISSN: 1920-454X
Titre abrégé: World J Oncol
Pays: Canada
ID NLM: 101564097
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
22
08
2023
accepted:
09
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is a leading cause of cancer-associated mortality worldwide. Despite being an essential component of systemic chemotherapy for advanced CRC, 5-fluorouracil (5-FU) clinical use has severe limitations, such as high toxicity, low selectivity and drug resistance. [V Effects on cellular viability, cell cycle progression, apoptosis and molecular mechanisms associated to [V In CRC cells, [V [V
Sections du résumé
Background
UNASSIGNED
Colorectal cancer (CRC) is a leading cause of cancer-associated mortality worldwide. Despite being an essential component of systemic chemotherapy for advanced CRC, 5-fluorouracil (5-FU) clinical use has severe limitations, such as high toxicity, low selectivity and drug resistance. [V
Methods
UNASSIGNED
Effects on cellular viability, cell cycle progression, apoptosis and molecular mechanisms associated to [V
Results
UNASSIGNED
In CRC cells, [V
Conclusions
UNASSIGNED
[V
Identifiants
pubmed: 38022396
doi: 10.14740/wjon1715
pmc: PMC10681791
doi:
Types de publication
Journal Article
Langues
eng
Pagination
540-550Informations de copyright
Copyright 2023, Sobol et al.
Déclaration de conflit d'intérêts
All authors have no conflict of interest to declare.
Références
Int J Cancer. 1992 Aug 19;52(1):98-104
pubmed: 1500231
J Neuroendocrinol. 2012 Apr;24(4):609-28
pubmed: 22375852
Anticancer Res. 2010 Dec;30(12):5049-54
pubmed: 21187489
Springerplus. 2015 Aug 19;4:428
pubmed: 26306290
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Mol Med Rep. 2014 Jun;9(6):2568-72
pubmed: 24737067
Curr Top Cell Regul. 1974;8(0):247-95
pubmed: 4371091
Am J Physiol. 1999 Feb;276(2):C370-8
pubmed: 9950764
Ann Oncol. 2023 Jan;34(1):10-32
pubmed: 36307056
Clin Exp Metastasis. 2016 Aug;33(6):589-600
pubmed: 27146156
Eur Surg Res. 2008;40(1):34-40
pubmed: 17890865
Breast Cancer Res Treat. 2013 Nov;142(1):9-18
pubmed: 24122393
Clin Cancer Res. 2016 Sep 15;22(18):4545-9
pubmed: 27401247
Cancer Sci. 2020 Sep;111(9):3142-3154
pubmed: 32536012
World J Gastroenterol. 2022 Jul 14;28(26):3027-3046
pubmed: 36051330
Vitam Horm. 2020;113:259-289
pubmed: 32138951
Cancer Lett. 2014 Jul 28;349(2):128-35
pubmed: 24746899
Invest New Drugs. 2020 Oct;38(5):1580-1587
pubmed: 32166534
Clin Med Res. 2007 Dec;5(4):228-37
pubmed: 18086907
Blood. 2010 Nov 25;116(22):4712-9
pubmed: 20716766
Pol J Pathol. 2017;68(3):269
pubmed: 29363921
Eur J Pharmacol. 2021 May 5;898:173994
pubmed: 33675784
Cancer Res. 2007 Jun 1;67(11):5248-57
pubmed: 17545604
Br J Cancer. 2019 Apr;120(8):797-805
pubmed: 30894685
Gastroenterol Rep (Oxf). 2020 Jun 15;8(3):192-205
pubmed: 32665851
J Gastrointest Cancer. 2012 Jun;43(2):279-87
pubmed: 21637966
Biochem Biophys Res Commun. 2015 Aug 28;464(3):848-54
pubmed: 26182875
Onco Targets Ther. 2018 Jul 02;11:3765-3774
pubmed: 29997437
Cell Death Differ. 2022 Nov;29(11):2177-2189
pubmed: 35484333
Cancer Res Treat. 2019 Apr;51(2):438-450
pubmed: 29879760
J Clin Invest. 2000 Jul;106(1):107-16
pubmed: 10880054
Int J Oncol. 2015;46(6):2335-45
pubmed: 25846632